Progress in research on diagnosis and treatment of pulmonary infection in patients with chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2022.05.008

Abstract

Abstract:

Pulmonary infection in patients with chronic kidney disease (CKD) is one of the common clinical comorbidities, and timely diagnosis and standardized treatment are crucial to the prognosis of the patients. This paper reviewed the epidemiology, hazards, classification, standardized diagnosis ideas, treatment principles and other aspects of pulmonary infection in patients with CKD.

Key words: Chronic kidney disease, Pulmonary infection, Comorbidity, Classification, Standardized diagnosis and treatment

Huan Li, Yushu Tang, Xuan Wang, Xisheng Xie. Progress in research on diagnosis and treatment of pulmonary infection in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 285-289.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.05.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/285

Figures/Tables 1

References 48

[1]	Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States [J]. Am J Kidney Dis, 2017, 69(3 Suppl 1): A7-A8.
[2]	Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies [J]. Chest, 2020, 158(5): 1896-1911.
[3]	Chen L, Zhou F, Li H, et al. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey [J]. BMJ Open, 2018, 8(2): e018709.
[4]	Chou CY, Wang SM, Liang CC, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study [J]. Medicine (Baltimore), 2014, 93(27): e174.
[5]	Ishigami J, Grams ME, Chang AR, et al. CKD and risk for hospitalization with infection: the atherosclerosis risk in communities (ARIC) study [J]. Am J Kidney Dis, 2017, 69(6): 752-761.
[6]	Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD [J]. Nat Rev Nephrol, 2017, 13(6): 344-358.
[7]	Bosco AM, Almeida BFM, Pereira PP, et al. The uremic toxin methylguanidine increases the oxidative metabolism and accelerates the apoptosis of canine neutrophils [J]. Vet Immunol Immunopathol, 2017, 185: 14-19.
[8]	Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system [J]. Lancet, 2013, 381(9865): 496-505.
[9]	Cheikh Hassan HI, Tang M, Djurdjev O, et al. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality [J]. Kidney Int, 2016, 90(4): 897-904.
[10]	Su G, Trevisan M, Ishigami J, et al. Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm creatinine measurement project [J]. Nephrol Dial Transplant, 2020, 35(11): 1894-1900.
[11]	Takada D, Kunisawa S, Matsubara T, et al. Developing and validating a multivariable prediction model for in-hospital mortality of pneumonia with advanced chronic kidney disease patients: a retrospective analysis using a nationwide database in Japan [J]. Clin Exp Nephrol, 2020, 24(8): 715-724.
[12]	Vandecasteele SJ, Ombelet S, Blumental S, et al. The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease [J]. Clin Kidney J, 2015, 8(3): 318-324.
[13]	汤颖，钟一红，龚邵敏，等. 终末期肾病血液透析患者感染死亡事件调查[J]. 中华肾脏病杂志，2011, 27(6): 406-410.
[14]	Contou D, d′Ythurbide G, Messika J, et al. Description and predictive factors of infection in patients with chronic kidney disease admitted to the critical care unit [J]. J Infect, 2014, 68(2): 105-115.
[15]	谢才德，兰蓝，罗婷，等. 慢性肾功能不全并发社区获得性肺炎的临床特点分析[J]. 重庆医学，2017, 46(8): 1120-1122.
[16]	Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia [J]. Antimicrob Agents Chemother, 2014, 58(9): 5262-5268.
[17]	陈亮，韩秀迪，李艳丽，等. 慢性肾脏病合并社区获得性肺炎的特征和危险因素[J]. 肾脏病与透析肾移植杂志，2019, 28(4): 336-342.
[18]	Lee JH, Moon JC. Clinical characteristics of patients with hemodialysis-associated pneumonia compared to patients with non-hemodialysis community-onset pneumonia [J]. Respir Med, 2016, 111: 84-90.
[19]	Viasus D, Garcia-Vidal C, Cruzado JM, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease [J]. Nephrol Dial Transplant, 2011, 26(9): 2899-2906.
[20]	Musiał K, Zwolińska D. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis [J]. Apoptosis, 2011, 16(7): 653-659.
[21]	Kawasaki S, Aoki N, Kikuchi H, et al. Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia? [J]. J Infect Chemother, 2011, 17(5): 640-645.
[22]	Wang PH, Wang HC. Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia [J]. BMC Infect Dis, 2016, 16: 377.
[23]	Song JU, Park HK, Kang HK, et al. Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia [J]. BMC Infect Dis, 2017, 17(1): 681.
[24]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China [J]. N Engl J Med, 2016, 375(9): 905-906.
[25]	Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients [J]. Intensive Care Med, 2020, 46(2): 298-314.
[26]	Kunihiro Y, Tanaka N, Kawano R, et al. Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography [J]. Eur Radiol, 2019, 29(11): 6089-6099.
[27]	Yu Q, Jia P, Su L, et al. Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a retrospective cohort study [J]. BMC Infect Dis, 2017, 17(1): 392.
[28]	Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia [J]. Respiration, 2018, 96(1): 52-65.
[29]	Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients [J]. Cochrane Database Syst Rev, 2014, 2014(10): CD005590.
[30]	Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children [J]. Clin Infect Dis, 2017, 64(2): e1-e33.
[31]	Gras J, De Castro N, Montlahuc C, et al. Clinical characteristics, risk factors, and outcome of tuberculosis in kidney transplant recipients: A multicentric case-control study in a low-endemic area [J]. Transpl Infect Dis, 2018, 20(5): e12943.
[32]	Di Pasquale MF, Sotgiu G, Gramegna A, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients [J]. Clin Infect Dis, 2019, 68(9): 1482-1493.
[33]	Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision [J]. J Fungi (Basel), 2017, 3(4): 57.
[34]	Lee HS, Park JY, Shin SH, et al. Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors [J]. Am J Clin Oncol, 2012, 35(2): 146-150.
[35]	中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志，2016, 39(4): 253-279.
[36]	周倩云. 不同抗生素治疗老年社区获得性肺炎临床对比观察[J]. 深圳中西医结合杂志，2016, 26(4): 128-129.
[37]	杭晨晨，王烁. 莫西沙星对老年肾功能不全社区获得性肺炎的治疗效果及安全性评价[J]. 中国急救医学，2014, (8): 685-688.
[38]	Zhang Y, Zhang F, Wang H, et al. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: results from the CARTIPS antimicrobial surveillance program [J]. J Glob Antimicrob Resist, 2016, 5: 36-41.
[39]	中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志，2018, 41(4): 255-280.
[40]	Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria [J]. Clin Microbiol Rev, 2012, 25(3): 450-470.
[41]	佘丹阳. 严峻耐药形势下肺炎治疗中的抗菌药物联合应用原则[J]. 中华结核和呼吸杂志，2018, 41(4): 252-254.
[42]	Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society [J]. Clin Infect Dis, 2016, 63(5): e61-e111.
[43]	Djordjevic ZM, Folic MM, Jankovic SM. Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit [J]. J Infect Public Health, 2017, 10(6): 740-744.
[44]	Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients [J]. J Antimicrob Chemother, 2016, 71(9): 2405-2413.
[45]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int Suppl, 2013, 3: 1-150.
[46]	Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults [J]. N Engl J Med, 2015, 372(12): 1114-1125.
[47]	McDonald HI, Thomas SL, Millett ERC, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records [J]. BMJ Open Diabetes Res Care, 2017, 5(1): e000332.
[48]	Ishigami J, Padula WV, Grams ME, et al. Cost-effectiveness of pneumococcal vaccination among patients with CKD in the United States [J]. Am J Kidney Dis, 2019, 74(1): 23-35.

分类	定义
社区获得性肺炎	非透析非住院慢性肾脏病患者罹患肺炎
医院获得性肺炎	维持性透析或者慢性肾脏病住院患者罹患肺炎
免疫低下合并肺炎	接受激素治疗[泼尼松20 mg，≥14 d或累积剂量>600 mg(或等效剂量激素)]、生物调节剂或其他免疫抑制药物治疗的慢性肾脏病患者罹患肺炎

分类	定义
社区获得性肺炎	非透析非住院慢性肾脏病患者罹患肺炎
医院获得性肺炎	维持性透析或者慢性肾脏病住院患者罹患肺炎
免疫低下合并肺炎	接受激素治疗[泼尼松20 mg，≥14 d或累积剂量>600 mg(或等效剂量激素)]、生物调节剂或其他免疫抑制药物治疗的慢性肾脏病患者罹患肺炎

Please choose a citation manager

Content to export